Rehmann Capital Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$760K Buy
1,708
+144
+9% +$64.1K 0.05% 268
2025
Q1
$758K Buy
1,564
+48
+3% +$23.3K 0.05% 267
2024
Q4
$610K Sell
1,516
-436
-22% -$176K 0.04% 305
2024
Q3
$906K Sell
1,952
-747
-28% -$347K 0.06% 228
2024
Q2
$1.27M Sell
2,699
-81
-3% -$38K 0.09% 172
2024
Q1
$1.16M Buy
2,780
+282
+11% +$118K 0.09% 185
2023
Q4
$1.02M Buy
2,498
+290
+13% +$118K 0.08% 188
2023
Q3
$768K Hold
2,208
0.07% 214
2023
Q2
$777K Sell
2,208
-361
-14% -$127K 0.07% 230
2023
Q1
$809K Sell
2,569
-27
-1% -$8.51K 0.08% 226
2022
Q4
$750K Buy
2,596
+68
+3% +$19.6K 0.08% 224
2022
Q3
$732K Buy
2,528
+220
+10% +$63.7K 0.08% 216
2022
Q2
$650K Sell
2,308
-492
-18% -$139K 0.07% 234
2022
Q1
$745K Buy
2,800
+392
+16% +$104K 0.07% 247
2021
Q4
$529K Sell
2,408
-165
-6% -$36.2K 0.05% 305
2021
Q3
$466K Sell
2,573
-81
-3% -$14.7K 0.04% 335
2021
Q2
$502K Buy
2,654
+551
+26% +$104K 0.05% 307
2021
Q1
$451K Buy
2,103
+279
+15% +$59.9K 0.05% 305
2020
Q4
$431K Sell
1,824
-204
-10% -$48.2K 0.05% 295
2020
Q3
$552K Buy
2,028
+109
+6% +$29.7K 0.07% 229
2020
Q2
$557K Buy
1,919
+398
+26% +$116K 0.08% 221
2020
Q1
$362K Buy
+1,521
New +$362K 0.06% 251
2019
Q3
$330K Buy
1,949
+1,509
+343% +$256K 0.04% 238
2019
Q2
$80.7K Sell
440
-1
-0.2% -$183 0.01% 683
2019
Q1
$81.1K Buy
441
+32
+8% +$5.89K 0.01% 659
2018
Q4
$67.8K Buy
409
+75
+22% +$12.4K 0.01% 504
2018
Q3
$64.4K Sell
334
-42
-11% -$8.1K 0.01% 712
2018
Q2
$63.9K Sell
376
-1,022
-73% -$174K 0.01% 698
2018
Q1
$228K Buy
+1,398
New +$228K 0.04% 342